Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: Glutaminase is a key enzyme, which supports elevated dependency of tumors on glutamine-dependent biosynthesis of metabolic intermediates. Dual targeting of glucose and glutamine metabolism by the mTOR inhibitor everolimus plus the oral glutaminase inhibitor telaglenastat showed preclinical synergistic anticancer effects, which translated to encouraging safety and efficacy findings in a phase I trial of 2L+ renal cell carcinoma (RCC). This study evaluated telaglenastat plus everolimus (TelaE) versus placebo plus everolimus (PboE) in patients with advanced/metastatic RCC (mRCC) in the 3L+ setting (NCT03163667). Patients and Methods: Eligible patients with mRCC, previously treated with at least two prior lines of therapy [including ≥1 VEGFR-targeted tyrosine kinase inhibitor (TKI)] were randomized 2:1 to receive E, plus Tela or Pbo, until disease progression or unacceptable toxicity. Primary endpoint was investigator-assessed progression-free survival (PFS; one-sided α <0.2). Results: Sixty-nine patients were randomized (46 TelaE, 23 PboE). Patients had a median three prior lines of therapy, including TKIs (100%) and checkpoint inhibitors (88%). At median follow-up of 7.5 months, median PFS was 3.8 months for TelaE versus 1.9 months for PboE [HR, 0.64; 95% confidence interval (CI), 0.34–1.20; one-sided P = 0.079]. One TelaE patient had a partial response and 26 had stable disease (SD). Eleven patients on PboE had SD. Treatment-emergent adverse events included fatigue, anemia, cough, dyspnea, elevated serum creatinine, and diarrhea; grade 3 to 4 events occurred in 74% TelaE patients versus 61% PboE. Conclusions: TelaE was well tolerated and improved PFS versus PboE in patients with mRCC previously treated with TKIs and checkpoint inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
Cited by
Amino acid metabolism in health and disease
Ling, Z.-N., Jiang, Y.-F., Ru, J.-N., Lu, J.-H., Ding, B., & Wu, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01569-3 · Cited by 545
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“…demonstrated a favorable safety profile and improved progression-free survival (PFS) in patients previously treated with tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors, suggesting the potential benefit of dual targeting glucose and glutamine metabolism in these cancers [223].”
BackgroundCancer cell metabolism and antitumour immunity
De Martino, M., Rathmell, J. C., Galluzzi, L., & Vanpouille-Box, C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01026-4 · Cited by 327
Emerging therapies in cancer metabolism
Xiao, Y., Yu, T.-J., Xu, Y., Ding, R., Wang, Y.-P., Jiang, Y.-Z., & Shao, Z.-M. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.006 · Cited by 256
Fan, Y., Xue, H., Li, Z., Huo, M., Gao, H., & Guan, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1345522 · Cited by 40
Metadata
- Authors
- Lee, C.-H., Motzer, R., Emamekhoo, H., Matrana, M., Percent, I., Hsieh, J. J., Hussain, A., Vaishampayan, U., Liu, S., McCune, S., Patel, V., Shaheen, M., Bendell, J., Fan, A. C., Gartrell, B. A., Goodman, O. B., Nikolinakos, P. G., Kalebasty, A. R., Zakharia, Y., Zhang, Z., Parmar, H., Akella, L., Orford, K., & Tannir, N. M.
- Venue
- Clinical Cancer Research
- Published
- 2022-05-16
- Volume
- 28
- Issue
- 15
- Pages
- 3248-3255
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W4280497867
- Cited by
- 113
- References
- 3
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-0061
- The paper
- Lee, C.-H., Motzer, R., Emamekhoo, H., Matrana, M., Percent, I., Hsieh, J. J., Hussain, A., Vaishampayan, U., Liu, S., McCune, S., Patel, V., Shaheen, M., Bendell, J., Fan, A. C., Gartrell, B. A., Goodman, O. B., Nikolinakos, P. G., Kalebasty, A. R., Zakharia, Y., . . . Tannir, N. M. (2022). Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-0061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.